Post

New research · Ophthalmology
Expert opinion on biological therapy · 2d
Cohort studyExpert opinion on biological therapy · 2026

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Achille Marino, Dariush Khaleghi Hashemian, Claudia Iannone … Cecilia Beatrice Chighizola
Read paper
OphthalmologyCohort study

Infliximab linked to higher risk of treatment change than adalimumab in JIA uveitis.

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Achille Marino … Cecilia Beatrice Chighizola
Expert opinion on biological therapy · 2026
Purpose

We assess prescription patterns and describe the long-term real-life effectiveness of different TNF inhibitors (TNFis) in juvenile idiopathic arthritis-related uveitis (JIA-U).

Methods

With JIA-U treated with TNFi were retrospectively enrolled.

Results

infliximab patients were about 3 times more likely to need a treatment switch

HR 3.06 (95% CI 1.41 to 6.63)
null = 11.416.63
CI excludes the null - significant
More results

Adalimumab was the most frequently prescribed TNFi (61%), followed by etanercept (19%), infliximab (15%), and golimumab (5%).

Overall, adalimumab showed the lowest complication rate (51%; p < 0.001) and median number of uveitis relapse (1; IQR 0-2; p = 0.012).

More results

Conversely, etanercept showed the highest median number of uveitis relapses (4; IQR 1-5).

The cumulative incidence curves for 'uveitis relapse' were similar among TNFi.

“
Conclusion · 1 of 2

All TNFis appear to be effective for long-term management of JIA-U.

Conclusion · 2 of 2

We observed some differences in the number of uveitis relapses and ocular complication rates favoring adalimumab over infliximab and etanercept, findings that need to be further confirmed in prospective studies.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment